Trials / Completed
CompletedNCT03762447
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 138 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB086550 in participants with advanced solid tumors who have failed prior treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB086550 | INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules. |
Timeline
- Start date
- 2018-12-10
- Primary completion
- 2023-11-17
- Completion
- 2023-11-17
- First posted
- 2018-12-03
- Last updated
- 2025-08-11
Locations
25 sites across 5 countries: United States, Belgium, France, Italy, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03762447. Inclusion in this directory is not an endorsement.